Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Made to measure: Choosing the optimal regimen in transplant-eligible NDMM
Endocrine therapy plus trastuzumab and pertuzumab shows excellent survival outcomes in HR and HER2 positive early BC
Addressing the rise of multiple myeloma in Rwanda
Hormonal receptor positive breast cancer adjuvant and metastatic indications
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
Trial argues strongly for the development of 1st-line biomarker selected strategies in pancreatic ductal adenocarcinoma
OncoAlert round up July 28th to August 3rd, 2023
Treatment decision guided by CTC count may improve long-term outcomes for mBC